Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00035269 |
This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae)
Condition | Intervention | Phase |
---|---|---|
Pneumonia, Pneumococcal Community Acquired Infections Gram-Positive Bacterial Infections |
Drug: Antibiotic |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Linezolid in the Treatment of Penicillin-Resistant Streptococcus Pneumoniae Pneumonia: An Open-Label, Non-Comparator Study |
Enrollment: | 230 |
Study Start Date: | December 2001 |
Estimated Study Completion Date: | May 2003 |
Ages Eligible for Study: | 13 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary.
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | M12600071, A5951056 |
Study First Received: | May 2, 2002 |
Last Updated: | July 2, 2007 |
ClinicalTrials.gov Identifier: | NCT00035269 |
Health Authority: | United States: Food and Drug Administration |
Pharmacia |
Bacterial Infections Gram-Positive Bacterial Infections Respiratory Tract Infections Respiratory Tract Diseases Streptococcal Infections Pneumonia, Bacterial |
Lung Diseases Community-Acquired Infections Pneumonia, Pneumococcal Linezolid Pneumococcal Infections Pneumonia |
Communicable Diseases Infection |